Charterhouse-backed SERB Pharmaceuticals completed the acquisition of reactive skin decontamination lotion assets from Emergent Biosolutions for $75m.

Charterhouse-backed SERB Pharmaceuticals, a global specialty pharmaceutical company with a growing portfolio of medicines for emergency care and rare diseases, completed the acquisition of reactive skin decontamination lotion assets from Emergent Biosolutions, an American multinational specialty biopharmaceutical company, for $75m. “The acquisition of RSDL® strengthens our position as the leading provider of medical countermeasures for chemical, biological, radiological and nuclear threats,” Jeremie Urbain, SERB Pharmaceuticals Chairman.